Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Target Price of $23.42 According to Analysts

Key Points

• Analysts have a consensus “Reduce” rating on Fresenius Medical Care, with four sell ratings and seven holds. The average 12-month price target is $23.42, modestly above the stock’s $21.93 opening price.
• The company’s latest quarterly results exceeded expectations, reporting $0.66 EPS versus the $0.62 estimate and revenue of $5.55 billion against the $5.48 billion forecast.
• Institutional ownership activity was mixed but included increased stakes from several investors; hedge funds and other institutions collectively own 8.37% of the stock.

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) have received a consensus recommendation of "Reduce" from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $23.42.

Several research firms recently weighed in on FMS. Berenberg Bank set a $24.00 target price on Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 29th. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price target on the stock. in a research note on Tuesday, July 28th. Sanford C. Bernstein lifted their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a "market perform" rating in a report on Thursday, August 6th. Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th.

Fresenius Medical Care AG & Co. KGaA Trading Down 1.1%

Shares of FMS opened at $21.93 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.43. The company has a market capitalization of $11.78 billion, a PE ratio of 11.37, a price-to-earnings-growth ratio of 4.10 and a beta of 0.74. The stock has a fifty day moving average of $22.60 and a two-hundred day moving average of $22.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.04. The business had revenue of $5.55 billion for the quarter, compared to analysts' expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. As a group, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors have recently bought and sold shares of the stock. Tidal Investments LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 96.0% during the second quarter. Tidal Investments LLC now owns 99,790 shares of the company's stock worth $2,256,000 after purchasing an additional 48,885 shares during the period. Moran Wealth Management LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company's stock valued at $7,846,000 after purchasing an additional 83,311 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 479.2% in the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company's stock valued at $4,893,000 after purchasing an additional 179,418 shares during the last quarter. Pzena Investment Management LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company's stock valued at $339,592,000 after purchasing an additional 299,986 shares during the last quarter. Finally, Ritholtz Wealth Management grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 252.7% during the 1st quarter. Ritholtz Wealth Management now owns 84,658 shares of the company's stock valued at $1,910,000 after buying an additional 60,652 shares during the period. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.